Serum resistin and adiponectin relationships with glucometabolic control in patients with type 2 diabetes mellitus

Khalid A. Al-Regaiey1, Syed S. Habib1, Laila Al Dokhi1, Anwar A. Jammah2, Mohammad M. Subhan3

1King Saud University, College of Medicine, Department of Physiology, Riyadh, Saudi Arabia; 2King Saud University, College of Medicine, Department of Medicine, Riyadh, Saudi Arabia; 3Plymouth University, School of Biomedical and Healthcare Sciences, United Kingdom

INTRODUCTION

It is well known that obesity increases the risk of developing type 2 diabetes mellitus (T2DM) [1]. Adipose tissue is a complex endocrine organ with potential implications on insulin resistance, obesity and diabetes. Many researches have resulted in identification of a large group of adipocyte-specific proteins, such as adiponectin, acylation-stimulating protein, resistin, leptin, which are involved in regulating glucose and lipid metabolism and insulin resistance in obesity and diabetes [1, 2, 3]. Therefore, high visceral fat and insulin resistance have been reported to be independently associated with prediabetes and T2DM [4]. Adipose tissue dysfunction is characterized by ectopic fat deposition in the abdominal viscera and liver, inflammatory and adipokine dysregulation, and insulin resistance, which may be a more important mediator of diabetes development than total fat mass as such [5, 6].

Adipocyte-specific proteins, such as adiponectin, acylation-stimulating protein, resistin and leptin, have recently been identified [7]. Resistin and adiponectin are important adipokines that regulate insulin sensitivity. Adiponectin, synthesized in the adipose tissue, appears to play an important role in inflammatory mechanisms, glycemic and lipid control, which cluster together to markedly increase the atherosclerotic risk in diabetes subjects. Plasma adiponectin concentrations are reported to be decreased in patients with obesity, T2DM, insulin resistance syndromes, dyslipidemia, and coronary artery disease [8–12]. Resistin is secreted by adipocytes and leads to insulin resistance in vivo and in vitro and is considered to be an important link between obesity and diabetes [13].

Lower levels of adiponectin in obese subjects are associated with higher levels of resistin and are considered to contribute to insulin resistance and accelerated atherogenesis [14]. Plasma adiponectin levels correlate negatively with adiposity, and serum adiponectin levels and waist–hip ratio (WHR) are independent predictors of high-sensitivity C-reactive protein levels in normoglycemic subjects [15, 16, 17]. Hence, both adiponectin and resistin have important biological activity on glucose and lipid metabolism and insulin resistance. This study aimed to assess and compare the relationships of resistin and adiponectin concentrations with glucometabolic control in patients with type 2 diabetes mellitus (T2DM).
metabolism. However, the comparison of these adipokines on glucometabolic control needs further investigation. Therefore, the aim of this study was to assess and compare the relationships of resistin and adiponectin concentrations with glucometabolic control in patients with T2DM.

**METHODS**

This case–control study was carried out at the Department of Physiology and Medicine, College of Medicine, and King Khalid University Hospital, King Saud University, Riyadh. The study was approved by the Institutional Review Board of the College of Medicine. A total of 191 subjects were selected for the study. Final analysis included 107 patients with T2DM (67 males and 40 females). The control group included 84 healthy subjects (45 males and 39 females) matched for age, sex, and weight, recruited from staff members and the patients’ companions. All the patients were diagnosed with T2DM based on American Diabetes Association criteria and were in stable metabolic condition with at least one year of duration of T2DM [18]. Patients with acute diabetes states, acute or chronic renal problems, thyroid diseases, acute and chronic infections, stroke, taking oral contraceptives or steroids, were excluded. Clinical and demographic data from all the participants was recorded on a predesigned form, which included weight, height, the body mass index (BMI), WHR measurements, and exercise habits. The patients were divided into a good and a poor glycemic control group based on a cut-off glycosylated hemoglobin (HbA1c) value of 7.5% [18]. After 10–12 hours of overnight fasting, venous blood samples were analyzed for total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL) and high-density lipoprotein (HDL), fasting blood glucose (FBG), HbA1c, basal insulin, adiponectin, and resistin levels. Human insulin, adiponectin, and resistin immunoaassays were carried out by quantitative standard sandwich enzyme-linked immunosorbent assay (ELISA) technique using a monoclonal antibody specific for resistin with kits supplied by R&D Systems, (Abingdon, United Kingdom). Insulin resistance was calculated by homeostasis model assessment of insulin resistance (HOMA-IR) using the formula HOMA-IR = (FPI (mU/L) × FPG (mmol/L)) / 22.5 [19].

Bioelectrical impendence analysis was used to measure body composition with InBody 3.0 (Biospace Inc., Seoul, Korea) body analyzer according to the manufacturer’s instructions. All assessments were made with the respondents being in the early morning fasting state, wearing light clothes, and after emptying of the urinary bladder. The machine calculated the amount of each tissue with the difference in electrical impedance [20].

**Statistical analysis**

The data was analyzed by IBM SPSS Statistics for Windows, Version 19.0 (IBM Corp., Armonk, NY, USA). Descriptive characteristics of the study patients were calculated as mean ± standard deviation. The tests applied for statistical analysis were Student’s t-test for normally distributed data and Mann–Whitney U-test for skewed data. We applied and used the linear-by-linear association p-value for significant difference at different quartiles of adiponectin and resistin levels in diabetes patients. Spearman’s correlations and multiple regression analysis were performed to show the predictors of adiponectin and resistin levels. A p-value of < 0.05 was taken as statistically significant.

**RESULTS**

This study reveals relationships between adiponectin and resistin concentrations with glycemic and lipid control in patients with T2DM. Table 1 shows comparison of descriptive characteristics and biochemical profile between control and diabetes patients. BMI, WHR, FBG, HbA1c, HOMA-IR, TC, and TG were significantly higher in individuals with diabetes compared to healthy volunteers. Exercise prevalence in each group was also compared and it was non-significant (Table1). T2DM patients were divided into good and poor glycemic control group based on a cut-off HbA1c value of 7.5%. Table 2 expresses the comparison of descriptive characteristics and biochemical profile between good and poor glycemic control in T2DM patients. BMI (p = 0.0257), HOMA-IR (p = 0.0002), and TG (p = 0.0006) were significantly higher in the poor glycemic control group than in the good glycemic control group.

Box plot represents serum adiponectin and resistin levels in controls, all subjects with diabetes, and in those with good and poor glycemic control (Figures 1 and 2). Serum resistin levels were significantly higher (p = 0.0259) (Figure 1) and serum adiponectin levels significantly lower (p = 0.0001) (Figure 2) in T2DM patients than in healthy controls.
We observed that serum adiponectin levels were significantly lower ($p = 0.0411$) in diabetes patients with poor glycemic control, compared to those with good glycemic control, but the difference was non-significant for resistin ($p = 0.8899$). Scatter plot in Figure 3 shows the relationship of adiponectin (a) and resistin (b) with glycosylated hemoglobin (HbA1c). Serum adiponectin levels were discordant with HbA1c ($r = -0.274$, $p = 0.004$). No relationship between HbA1c and resistin levels was observed ($r = 0.017$, $p = 0.866$). Linear-by-linear association of HbA1c% at different quartiles of adiponectin and resistin levels in diabetes patients was also determined. There was a significant trend of better glycemic control at increasing levels of adiponectin levels ($p = 0.042$), while the trend was not significant for resistin levels ($p = 0.904$).

Multiple regression analysis was performed keeping adiponectin and resistin as dependent variables to determine their predictive factors (Table 3). Significant predictors of adiponectin levels were FBS, insulin, HOMA-IR, and HbA1c. For resistin, none of the variables was significant. Table 4 expresses the proportion of patients using medications for diabetes and comorbidities in patients with T2DM.

**DISCUSSION**

The present study aims to assess and compare the relationships of resistin and adiponectin concentrations with subjects. We observed that serum adiponectin levels were significantly lower ($p = 0.0411$) in diabetes patients with poor glycemic control, compared to those with good glycemic control, but the difference was non-significant for resistin ($p = 0.8899$). Scatter plot in Figure 3 shows the relationship of adiponectin (a) and resistin (b) with glycosylated hemoglobin (HbA1c). Serum adiponectin levels were discordant with HbA1c ($r = -0.274$, $p = 0.004$). No relationship between HbA1c and resistin levels was observed ($r = 0.017$, $p = 0.866$). Linear-by-linear association of HbA1c% at different quartiles of adiponectin and resistin levels in diabetes patients was also determined. There was a significant trend of better glycemic control at increasing levels of adiponectin levels ($p = 0.042$), while the trend was not significant for resistin levels ($p = 0.904$).
adiponectin were useful indicators of T2DM. Moreover, as independent predictors of adiponectin. Glucose and tumor necrosis factor-α (TNF-α), and BMI were identified IR, and correlated positively with HDL. Diabetes status, correlated negatively with TG, interleukin-6, and HOMA-
diabetes status. Among non-obese subjects, adiponectin supports the hypothesis that increased adiponectin levels control. Similar to a report by Schulze et al. [21], our study glycemic control, compared to those with good glycemic control. Similar to a report by Schulze et al. [21], our study supports the hypothesis that increased adiponectin levels might be associated with better lipid and glycemic control with reduced inflammation in patients with T2DM. Measures that could increase adiponectin levels might be valuable targets for decreasing the higher coronary artery disease risk in diabetes.

In another similar study, adiponectin was found to be significantly decreased in T2DM patients as compared to normal control subjects. Adiponectin levels were negatively associated with high-sensitivity C-reactive protein, LDL-C, HbA1c, TG, TC, and positively with HDL-C. HbA1c had a negative correlation with serum adiponectin. This shows that adiponectin may play an important role in the pathogenesis of diabetes, and may emerge as an independent predictor of the development of T2DM [22]. Nayak et al. [23] showed that adiponectin decreases with increasing adiposity and insulin resistance regardless of diabetes status. Among non-obese subjects, adiponectin correlated negatively with TG, interleukin-6, and HOMA-IR, and correlated positively with HDL. Diabetes status, tumor necrosis factor-α (TNF-α), and BMI were identified as independent predictors of adiponectin. Glucose and adiponectin were useful indicators of T2DM. Moreover, insulin-mediated glucose turnover was significantly affected by adiponectin and TNF-α [25]. Adiponectin negatively correlated with BMI after adjusting for age, sex, and diabetes status [24]. In an interesting study, Lau et al. [25] proposed a novel adiponectin–resistin (AR) index by taking into account both adiponectin and resistin levels to provide a better indicator of the metabolic homeostasis and metabolic disorders. A novel insulin resistance (IRAR) index was derived to provide an improved diagnostic biomarker of insulin sensitivity.

Adipocytokines that have been implicated in the pathogenesis of metabolic syndrome include TNF-α, interleukin-6, angiotensinogen, leptin, plasminogen activator inhibitor-1, and resistin [26]. The present study supports the evidence that resistin plays an important role in the pathogenesis of obesity and insulin resistance. We reported previously that higher resistin levels in T2DM have a significant positive correlation with body fat mass [27]. However, in the present study, although T2DM patients had higher resistin levels, the effect of glycemic control on resistin levels was not significant. In a study on Chinese T2DM patients, 16 weeks of liraglutide administration led to increased adiponectin and decreased resistin levels compared to glimepiride-treated subjects, while inducing similar glycemic changes [28]. Adiponectin, leptin, and resistin levels are affected by the use of anti-diabetes drugs among which glimepiride shows more effect on adiponectin and resistin levels, while leptin gets affected more by metformin. It shows that the adipokine levels are not affected by diabetes only, suggesting that their alterations in T2DM may be due to obesity. Therefore, there might be important links between adiposity and insulin resistance [29].

The limitation of the present work is its cross-sectional design and small sample size. We recommend further large-scale prospective studies to additionally explore the true homeostatic roles of adiponectin and resistin in patients with T2DM. Since they are related to glucose and lipid metabolism, it would be worth studying them as an integrated approach in relation to different pharmacological interventions and physical fitness programs. They may prove to be useful integrated biomarkers to predict metabolic dysregulation and cardiovascular risk in T2DM.

**CONCLUSION**

T2DM patients have significantly higher resistin and lower adiponectin levels when compared to healthy controls. Adiponectin levels were significantly lower in patients with poor glycemic control. However, the effect of glycemic control on resistin levels was not significant.

**ACKNOWLEDGMENT**

The authors are thankful to Dr. Shaikh Mujeeb Ahmed and Mr. James Chu for collection of data and blood assays. We are thankful to King Abdul Aziz City for Science and Technology for supporting this project (Project No. 26-60).

---

**Table 3.** Multiple regression analysis for prediction of adiponectin and resistin levels in T2DM patients

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Adiponectin (ng/ml) Standardized Beta Coefficients</th>
<th>Resistin (ng/ml) Standardized Beta Coefficients</th>
</tr>
</thead>
<tbody>
<tr>
<td>FBS (mmol/L)</td>
<td>1.498 0.015 0.481 0.507</td>
<td>P</td>
</tr>
<tr>
<td>Insulin (µU/ml)</td>
<td>1.524 0.018 0.518 0.493</td>
<td>P</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>-2.317 0.016 -0.855 0.450</td>
<td>P</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>-0.237 0.014 0.284 0.182</td>
<td>P</td>
</tr>
<tr>
<td>TG (mmol/L)</td>
<td>-0.150 0.315 -0.201 0.268</td>
<td>P</td>
</tr>
<tr>
<td>TC (mmol/L)</td>
<td>-0.260 0.122 0.153 0.448</td>
<td>P</td>
</tr>
<tr>
<td>HDL (mmol/L)</td>
<td>0.074 0.618 -0.089 0.620</td>
<td>P</td>
</tr>
<tr>
<td>LDL (mmol/L)</td>
<td>0.133 0.472 -0.401 0.079</td>
<td>P</td>
</tr>
<tr>
<td>Duration (years)</td>
<td>0.268 0.063 -0.186 0.283</td>
<td>P</td>
</tr>
</tbody>
</table>

BMI – body mass index; WHR – waist–hip ratio; FBS – fasting blood glucose; HbA1c – glycosylated hemoglobin; TC – total cholesterol; TG – triglycerides; LDL – low-density lipoprotein; HDL – high-density lipoprotein

**Table 4.** Use of medications for diabetes and comorbidities in patients with T2DM

<table>
<thead>
<tr>
<th>Medicines for diabetes</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biguanides</td>
<td>14 (13.1)</td>
</tr>
<tr>
<td>Sulphonylureas</td>
<td>25 (23.4)</td>
</tr>
<tr>
<td>Glinides</td>
<td>11 (10.3)</td>
</tr>
<tr>
<td>Alpha-glucosidase inhibitors</td>
<td>21 (11.2)</td>
</tr>
<tr>
<td>Thiazolidinedione</td>
<td>23 (21.5)</td>
</tr>
<tr>
<td>Lipid-lowering medicines</td>
<td>25 (23.4)</td>
</tr>
</tbody>
</table>
REFERENCES

Однос серумског резистина и адипонектина и глукометаболичка контрола код болесника са дијабетесом мелитусом типа 2

Халид А. ел Регаиеј, Сајед Ш. Хабиб, Лејла ел Дохи, Анвар А. Џамах, Мохамед М. Субхан

1Универзитет краља Сауда, Медицински колеџ, Катедра за физиологију, Ријад, Саудијска Арабија;
2Универзитет краља Сауда, Медицински колеџ, Катедра за медицину, Ријад, Саудијска Арабија;
3Универзитет у Плимуту, Факултет биомедицинских и здравствених наука, Плимут, Велика Британија

Увод/Циљ Адипонектин и резистин су адипокини који играју важну улогу у регулисању шећера у крви, бета-оксидацији у мишићима и инсулинској резистенцији. Циљ ове студије је био да процени и упореди односе концентрација резистина и адипонектина са глукометаболичком контролом код болесника са шећерном болешћу типа 2 (ШБТ2).

Методе Испитан је укупно 191 испитаник. Коначна селекција обухватала је 107 болесника са ШБТ2 (67 мушкараца и 40 жена) и 84 здравих, контролних особа (45 мушкараца и 39 жена). Анализирани су узорци венске крви за глукозу (ВГ), гликозиловани хемоглобин (HbA1c), инсулин, липиди (укупни холестерол – УХ, триглицериди – ТГ), адипонектин и резистин. Грађа тела оцењена је код свих и то индексом телесне масе (ИТМ) и односом структ–кукови (ОСК).

Резултати: ИТМ, ОСК, ВГ, HbA1c, инсулинска резистенција (ИР), УХ и ТГ били су значајно већи код осoba с дијабетесом у поређењу са здравим добровољцима. Ниво резистина у серуму био је значајно виши (p = 0,0259), а ниво серумског адипонектина значајно нижи (p = 0,0001) код ШБТ2 него код контролних субјеката. Ниво адипонектина били су значајно нижи код ШБТ2 него код контролних субјеката (p = 0,0001) код болесника са лошом контролом гликемије у поређењу са онима са добром гликемијском контролом, док је разлика нивоа резистина била беззначајна (p = 0,8899). Линеарна корелација показала је значајан тренд боље контроле гликемије код повећања нивоа адипонектина (p = 0,042), док тренд није био значајан за ниво резистина (p = 0,904). Мултипла регресионана анализа откривла је ВГ, инсулин, ИР и HbA1c као значајне предикторе адипонектина.

Закључак: Болесници са ШБТ2 имају значајно повишен резистин и снижен адипонектин у поређењу са здравим особама. Ниво адипонектина су значајно нижи код болесника са слабом контролом гликемије. Кључне речи: адипонектин; резистин; дислипидемија; шећерна болест тип 2

DOI: https://doi.org/10.2298/SARH170124200R